Component of von Hippel-Lindau tumor suppressor complex and SCF ubiquitin ligase
AssigneeOklahoma Medical Research Foundation
InventorsJoan W. Conaway, Ronald C. Conaway, Takumi Kamura
Life of this patent
Estimating the term…
Loading patent…
AssigneeOklahoma Medical Research Foundation
InventorsJoan W. Conaway, Ronald C. Conaway, Takumi Kamura
Estimating the term…
Rbx1, an evolutionarily conserved Cullin-interacting RING-H2 finger protein, has been discovered. Mammalian Rbx1 has been identified as a component of the CUL2-containing VHL complex. An Rbx1 homolog from S. cerevisiae has also been identified as a subunit and activator of the Cdc53-containing SCFCdc4 ubiquitin ligase required for ubiquitination of the cdk inhibitor Sic1 and for the G1/S cell cycle transition in yeast, providing a link between the multiprotein VHL tumor suppressor complex and cellular ubiquitination. The Rbx1 protein acts as a cellular marker useful (1) in detecting a possible predisposition to certain carcinomas, (2) as a molecular target for treating those carcinomas therapeutically. (3) as a target for inhibition by drugs that manipulate the growth of cells, and (4) as a research tool to better understand the various complex mechanisms of cell ubiquitination, binding of certain activator proteins, fibronectin deposition and other aspects of the cellular division process.
An isolated and purified biologically active Ring box protein comprising a polypeptide having an amino acid sequence corresponding to SEQ ID NO:1.
A recombinant Ring box protein comprising a polypeptide having an amino acid sequence corresponding to SEQ ID NO:1.
Dependencies are inferred from the claim text.